Latest Conference Articles

EloraTZP cut body weight by up to 23.3% and A1C by up to 2.9% at 48 weeks vs 14.8% and 2.4% with tirzepatide 15 mg in a phase 2b trial.

Check out highlights from news published on Day 1 of the EADV Congress 2026, spanning CSU, atopic dermatitis, HS, and more.

Bhatia discusses 52-week extension data showing denifanstat sustained acne control with a favorable long-term safety profile, presented at EADV 2026.

Tulisokibart met its HiSCR50 primary endpoint at 16 weeks in the phase 2b MK-7240-012 trial assessing moderate to severe hidradenitis suppurativa.

Intralesional BO-112 met its main endpoint in the phase 2b SPOTLIGHT-204 trial, with 61% of patients with resectable basal cell carcinoma responding.

The international SkinObservatory study found climate-related skin disease disproportionately affecting low-income nations at EADV 2026.

All 3 zumilokibart doses met the EASI-75 primary end point vs placebo at Week 16 in AbbVie's phase 2 APEX Part B atopic dermatitis study.

Dupilumab improved overall CU-Q2oL scores and 22 of 23 items vs placebo at 24 weeks in omalizumab-naive CSU, per a pooled CUPID A and C analysis.

Get a head start on one of the biggest heart failure conferences of the year with our HFSA 2026 preview.

Manju Dawkins, MD, discusses Skin Angels, why clinicians belong in dermatology innovation, and her work to reduce injection pain and needle anxiety.

This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.

Kazem Rahimi, MD, discusses his recent IPD analysis highlighting the consistent relative risk reduction of first cardiovascular event with BP-lowering drugs.

van Ingen, of Radboud University Medical Center, discusses the ENCORE trial's patient-reported endpoint for ALIS in MAC lung disease.

van Ingen, of Radboud University Medical Center discusses data showing add-on ALIS improved durable culture conversion in newly diagnosed MAC lung disease.

Selvanayagam shares his thoughts on whether ICDs’ improvements in sudden cardiac death are worth the reduced quality of life.

Joseph Selvanayagam, MBBS, discusses the potential of implantable cardioverter-defibrillators to reduce sudden cardiac death among younger patients.

Read 6 late-breaking updates from ERS Congress 2026 that clinicians managing respiratory disease should know.

At ERS 2026, pulmonologists framed oral STAT6 degradation—led by Kymera's KT-621—as a potential biologic-like, access-expanding approach.

Astrid Paul Nordin, MD, PhD, discusses the results of the IDEAL-AF trial, highlighting the efficacy of including LVZ on top of PVI.

Anjali Owens, MD, discusses the long-term extension of the EXPLORER-HCM trial, demonstrating mavacamten’s safety and efficacy up to 5 years after initiation.

Sten Rubertsson, MD, PhD, discusses the results of the DISCO study, which compared immediate to deferred angiography in patients without ST-elevation following cardiac arrest.

George, of Royal Brompton Hospital discusses a phase 2a post hoc analysis showing increases in lung volume and reduced ILD.

John Ostrominski, MD, discusses his analysis of the FINEARTS-HF trial, which showed finerenone’s improvements despite CKD, ASCVD, and/or metabolic disease.

In this Q&A, Leon Kircik, MD, discusses challenging watch-and-wait for molluscum contagiosum with berdazimer gel, 10.3%, at LEADderm 2026.

Bhatt also discusses how these findings inform the choice between dupilumab and mepolizumab under GOLD 2026.

Wuyts, of University Hospitals Leuven discusses interim FIBRONEER-ON open-label extension data showing nerandomilast's favorable safety profile.

Jonathan Piccini, MD, discusses his presentation at ESC 2026 discussing the potential benefits of catheter ablation in concomitant HFpEF and AF.

Marlies Wijsenbeek, MD, PhD, of Erasmus MC discusses BI 1839100, a TRPA1 antagonist, which missed its week-4 endpoint in a phase 2/2b trial.